A phase III study of REGN-2810 in cervical cancer

Trial Profile

A phase III study of REGN-2810 in cervical cancer

Phase of Trial: Phase III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs REGN 2810 (Primary)
  • Indications Cervical cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Aug 2017 New trial record
    • 03 Aug 2017 According to a Regeneron Pharmaceuticals media release, the company plans to initiate this study in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top